0
Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

Treatment in Psychiatry   |    
Antipsychotic Treatment in Breast Cancer Patients
Tahir Rahman, M.D.; Charles V. Clevenger, M.D., Ph.D.; Virginia Kaklamani, M.D.; John Lauriello, M.D.; Austin Campbell, Pharm.D.; Kari Malwitz, M.D.; Robert S. Kirkland
Am J Psychiatry 2014;171:616-621. doi:10.1176/appi.ajp.2013.13050650
View Author and Article Information

Dr. Clevenger has served on an advisory panel for Bristol-Myers Squibb. Dr. Lauriello has received research support from Sunovion, served on monitoring boards for Janssen and Shire, and served on advisory panels and in CME activities for Sunovion and Otsuka. The other authors report no financial relationships with commercial interests.

From the Department of Psychiatry, University of Missouri, Columbia; and the Departments of Pathology and Oncology, Northwestern University, Chicago.

Address correspondence to Dr. Rahman (rahmantahi@health.missouri.edu).

Copyright © 2014 by the American Psychiatric Association

Received May 15, 2013; Revised August 11, 2013; Accepted August 19, 2013.

Abstract

Special consideration is required when prescribing antipsychotic drugs for patients with an existing diagnosis of breast cancer. The package inserts of all approved antipsychotics contain precautions regarding their administration in this patient group. These drugs are well known to elevate serum prolactin levels to varying degrees. Overexpression of the prolactin receptor is seen in more than 95% of human breast cancers. Many genes that are activated by the prolactin receptor are associated with tumorigenesis and cancer cell proliferation. The authors discuss the pathophysiology, clinical implications, and pertinent preclinical data and make specific recommendations regarding the use of antipsychotics in patients with breast cancer.

Abstract Teaser
Figures in this Article

Your Session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Anchor for Jump
TABLE 1.Effects of Antipsychotics on Prolactin Levelsa
Table Footer Note

a ULN=upper limit of normal. The ULN varied in the studies reviewed, but normal prolactin levels are typically considered to be <20 ng/mL. Data drawn from references 2633.

+

References

Clevenger  CV;  Furth  PA;  Hankinson  SE;  Schuler  LA:  The role of prolactin in mammary carcinoma.  Endocr Rev 2003; 24:1–27
[CrossRef] | [PubMed]
 
Clevenger  CV;  Zheng  J;  Jablonski  EM;  Galbaugh  TM;  Fang  F:  From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics.  J Mammary Gland Biol Neoplasia 2008; 13:147–156
[CrossRef] | [PubMed]
 
Wagner  KU;  Rui  H:  Jak2/Stat5 signaling in mammogenesis, breast cancer initiation, and progression.  J Mammary Gland Biol Neoplasia 2008; 13:93–104
[CrossRef] | [PubMed]
 
Clevenger  CV;  Chang  WP;  Ngo  W;  Pasha  TL;  Montone  KT;  Tomaszewski  JE:  Expression of prolactin and prolactin receptor in human breast carcinoma: evidence for an autocrine/paracrine loop.  Am J Pathol 1995; 146:695–705
[PubMed]
 
Ginsburg  E;  Vonderhaar  BK:  Prolactin synthesis and secretion by human breast cancer cells.  Cancer Res 1995; 55:2591–2595
[PubMed]
 
Maus  MV;  Reilly  SC;  Clevenger  CV:  Prolactin as a chemoattractant for human breast carcinoma.  Endocrinology 1999; 140:5447–5450
[PubMed]
 
Zheng  J;  Koblinski  J;  Dutson  LB;  Feeney  YB;  Clevenger  CV:  Peptidyl-prolyl isomerase regulation of Jak2 activation and the progression of human breast cancer.  Cancer Res 2008; 68:7769–7778
[PubMed]
 
Hankinson  SE;  Willett  WC;  Michaud  DS;  Manson  JE;  Colditz  GA;  Langcope  C;  Rosner  B;  Speizer  FE:  Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women.  J Natl Cancer Inst 1999; 91:629–634
[PubMed]
 
Tworoger  SS;  Sluss  P;  Hankinson  SE:  Association between plasma prolactin concentrations and risk of breast cancer among predominantly premenopausal women.  Cancer Res 2006; 66:2476–2482
[PubMed]
 
Wang  DY;  Stepniewska  KA;  Allen  DS;  Fentiman  IS;  Bulbrook  RD;  Kwa  HG;  DeStavola  BL;  Reed  MJ:  Serum prolactin levels and their relationship to survival in women with operable breast cancer.  J Clin Epidemiol 1995; 48:959–968
[PubMed]
 
Lissoni  P;  Barni  S;  Cazzaniga  M;  Ardizzoia  A;  Rovelli  F;  Tancini  G;  Brivio  F;  Frigerio  F:  Prediction of recurrence in operable breast cancer by postoperative chances in prolactin secretion.  Oncology 1995; 52:439–442
[PubMed]
 
Wang  PS;  Walker  AM;  Tsuang  MT;  Orav  EJ;  Glynn  RJ;  Levin  R;  Avorn  J:  Dopamine antagonists and the development of breast cancer.  Arch Gen Psychiatry 2002; 59:1147–1154
[PubMed]
 
Ji  J;  Sundquist  K;  Ning  Y;  Kendler  KS;  Sundquist  J;  Chen  X:  Incidence of cancer in patients with schizophrenia and their first-degree relatives: a population-based study in Sweden.  Schizophr Bull 2013; 39:527–536
[PubMed]
 
Bazan  JF:  Structural design and molecular evolution of a cytokine receptor superfamily.  Proc Natl Acad Sci USA 1990; 87:6934–6938
[PubMed]
 
Reynolds  C;  Montone  KT;  Powell  CM;  Tomaszewski  JE;  Clevenger  CV:  Expression of prolactin and its receptor in human breast carcinoma.  Endocrinology 1997; 138:5555–5560
[PubMed]
 
Fiorillo  AA;  Medler  TR;  Feeney  YB;  Wetz  SM;  Tommerdahl  K;  Clevenger  CV:  The prolactin receptor transactivation domain is associated with steroid hormone receptor expression and malignant progression of breast cancer.  Am J Pathol 2013; 182:217–233
[PubMed]
 
Li  Y;  Clevenger  CV;  Minkovsky  N;  Kumar  KG;  Raghunath  PN;  Tomaszewski  JE:  Stabilization of prolactin receptor in breast cancer cells.  Oncogene 2006; 25:1896–1902
[PubMed]
 
DaSilva  L;  Rui  H;  Erwin  RA;  Howard  OM;  Kirken  RA;  Malabarba  MG:  Prolactin recruits STAT1, STAT3, and STAT5 independent of conserved receptor tyrosines TYR402, TYR479, TYR515, and TYR580.  Mol Cell Endocrinol 1996; 117:131–140
[PubMed]
 
Clevenger  CV:  Role of Stat family transcription factors in human breast cancer.  Am J Pathol 2004; 165:1449–1460
[PubMed]
 
Galbaugh  T;  Feeney  Y;  Clevenger  C:  Prolactin receptor-integrin crosstalk mediated by SIRPa in breast cancer cells.  Mol Cancer Res 2010; 8:1413–1424
[PubMed]
 
Fiorillo  AA;  Medler  TR;  Liu  Y;  Tommerdahl  K;  Feeney  YB;  Clevenger  CV:  The transactivating properties of nuclear prolactin receptor are mediated through its inducible interaction with the chromatin associated protein, HMGN2.  Mol Endocrinol 2011; 25:1550–1564
[PubMed]
 
Rose-Hellekant  TA;  Arendt  LM;  Schroeder  MD;  Gilchrist  K;  Sandgren  EP;  Schuler  LA:  Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice.  Oncogene 2003; 22:4664–4674
[PubMed]
 
Wennbo  H;  Gebre-Medhin  M;  Griti-Linde  A;  Ohlsson  C;  Isaksson  OGP;  Tornell  J:  Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice.  J Clin Invest 1997; 100:2744–2751
[PubMed]
 
Arendt  LM;  Rose-Hellenkant  TA;  Sandgren  EP;  Schuler  LA:  Prolactin potentiates transforming growth factor alpha induction of mammary neoplasia in transgenic mice.  Am J Pathol 2006; 168:1365–1374
[PubMed]
 
Ren  S;  Cai  HR;  Li  M;  Furth  PA:  Loss of Stat5a delays mammary cancer progression in a mouse model.  Oncogene 2002; 21:4355–4359
 
Perkins  DO:  Antipsychotic-induced hyperprolactinemia: pathophysiology and clinical consequences.  Adv Stud Med 2004; 4:S982–S986
 
Bostwick  JR;  Guthrie  SK;  Ellingrod  VL:  Antipsychotic-induced hyperprolactinemia.  Pharmacotherapy 2009; 29:64–73
[PubMed]
 
Cookson  J;  Hodgson  R;  Wildgust  HJ:  Prolactin, hyperprolactinaemia, and antipsychotic treatment: a review and lessons for treatment of early psychosis.  J Psychopharmacol 2012; 26:42–51
[PubMed]
 
Madhusoodanan  S;  Parida  S;  Jimenez  C:  Hyperprolactinemia associated with psychotropics: a review.  Hum Psychopharmacol 2010; 25:281–297
[PubMed]
 
Knegtering  R;  Baselmans  P;  Castelein  S;  Bosker  F;  Bruggeman  R;  van den Bosch  RJ:  Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels.  Am J Psychiatry 2005; 162:1010–1012
[PubMed]
 
Hummer  M;  Huber  J:  Hyperprolactinaemia and antipsychotic therapy in schizophrenia.  Curr Med Res Opin 2004; 20:189–197
[PubMed]
 
Hamner  M:  The effects of atypical antipsychotics on serum prolactin levels.  Ann Clin Psychiatry 2002; 14:163–173
[PubMed]
 
Leucht  S;  Ciprian  A;  Spineli  L;  Mavridis  D;  Orey  D;  Richter  F;  Samara  M;  Barbui  C;  Engel  RR;  Geddes  JR;  Kissling  W;  Stapf  MP;  Lässig  B;  Salanti  G;  Davis  JM:  Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.  Lancet 2013; 382:951–962
[PubMed]
 
Jacobson  EM;  Hugo  ER;  Tuttle  TR;  Papoian  R;  Ben-Jonathan  N:  Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor.  Trends Endocrinol Metab 2010; 21:691–698
[PubMed]
 
Seeman  MV:  Preventing breast cancer in schizophrenia.  Acta Psychiatr Scand 2011; 123:107–117
[PubMed]
 
Kaklamani  VG;  Hoffmann  TJ;  Thornton  TA;  Hayes  G;  Chlebowski  R;  Van Horn  L;  Mantzoros  C:  Adiponectin pathway polymorphisms and risk of breast cancer in African Americans and Hispanics in the Women's Health Initiative.  Breast Cancer Res Treat 2013; 139:461–468
[PubMed]
 
Liang-Jen  W;  Shao-Chun  R;  Yu-Shu  H;  Cheng-Cheng  H;  Chih-Ken  C:  Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.  Prog Neuropsychopharmacol Biol Psychiatry 2013; 40:260–266
[PubMed]
 
Seeman  MV:  Loss of libido in a woman with schizophrenia.  Am J Psychiatry 2013; 170:471–475
[PubMed]
 
References Container
+
+

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content
Articles
Books
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 9.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 1.  >
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 21.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 15.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 1.  >
Topic Collections
Psychiatric News
APA Guidelines
PubMed Articles